Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children - sprookjes - yvandenbroek - TriplyDB

Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children

Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children

http://www.wikidata.org/entity/Q35694752

about

Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence.A Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment Outcome Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia Randomized single-blinded non-inferiority trial of 7 mg/kg pentamidine isethionate versus 4 mg/kg pentamidine isethionate for cutaneous leishmaniaisis in Suriname Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update.An update on pharmacotherapy for leishmaniasis Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide Cutaneous Leishmaniasis: Current Treatment Practices in the USA for Returning Travelers Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages: IMPACT ON INTRACELLULAR SURVIVAL OF LEISHMANIA (VIANNIA) PANAMENSIS.Clinical and epidemiologic profile of cutaneous leishmaniasis in Colombian children: considerations for local treatment.Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species.Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis.Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.Parasitic diseases in travelers: a focus on therapy.LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014.Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children? A Critically Appraised Topic.Cutaneous leishmaniasis in travellers: a focus on epidemiology and treatment in 2015.Balamuthia mandrillaris Encephalitis: Survival of a Child With Severe Meningoencephalitis and Review of the Literature.Susceptibility to Miltefosine in Brazilian Clinical Isolates of Leishmania (Viannia) braziliensis.Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment.American cutaneous leishmaniasis in infancy and childhood.3M-052 as an adjuvant for a PLGA microparticle-based Leishmania donovani recombinant protein vaccine.Novel arylalkylamine compounds exhibits potent selective antiparasitic activity against Leishmania major.Evaluation of the leishmanicidal and cytotoxic potential of essential oils derived from ten colombian plants.Travelers with cutaneous leishmaniasis cured without systemic therapy.Failure of fluconazole in treating cutaneous leishmaniasis caused by Leishmania guyanensis in the Brazilian Amazon: An open, nonrandomized phase 2 trial.Why miltefosine-a life-saving drug for leishmaniasis-is unavailable to people who need it the most.The Binomial Parasite-Host Immunity in the Healing Process and in Reactivation of Human Tegumentary Leishmaniasis.

P2860

Q27022964-763C06D6-9D76-4123-990A-868597D6D79F Q27303693-82E2FFE4-62C0-40FA-9B97-36D406E08C85 Q28088410-1EF21355-69DE-4F22-861C-13E51C92F27E Q28271849-0F2B8240-0990-47FB-BED5-FC4C197DB3F5 Q28539068-3683DD09-883F-472B-AE0B-0A1AD731F784 Q28544790-77DE5FBA-9699-47C2-B803-12A8EC5AF07B Q30275257-343EEEC9-63EA-44C3-9D1F-A614D758D72B Q33570722-C0EE9F2E-26C4-48B2-9876-DDAAE448A618 Q33602811-9F7B50C2-C506-4FC0-B084-2B453541B86B Q34700686-7FE70595-1209-4659-8232-013BBB0AA041 Q34945204-2D88BDFD-E5D6-4550-AC81-91B955465CE1 Q35160905-3D50B5FA-DABC-44B0-B4AE-428365BDBA13 Q35180338-E0735281-8DFA-4953-8577-9C9F6692943F Q36086339-A2E4490F-9B48-405C-991B-E9839119BB0B Q36850042-3F2A8685-4331-443C-8DE1-545646946E5C Q37089640-6514BBC6-F97F-4116-A548-B30BF5940C87 Q37544280-E95C0E7E-7E3A-4675-9DDA-5073F3D5FF57 Q37669845-0A7AAADC-6C4B-454F-B666-117B9E5AEA1C Q38156421-3F54806A-66D7-453A-AD11-6CB55FDB7B4C Q38192001-E6E5D025-047C-48C7-9031-7F1A716B912D Q38205451-C268DC9A-D9B5-4F8B-A649-ECAAD609E0B5 Q38263615-7C287FF1-BF7C-4FC8-B393-0B0B984D6468 Q38511211-100C0748-B3C7-4ECF-A35E-4F7CB3237288 Q38654933-670BDFB6-030A-4788-A2B8-BDE8F6689346 Q38995293-22DA38B9-63B8-4410-8D54-E35D25E7F650 Q39273435-3AEA30E5-2369-4FE8-896A-B6B36EEC4095 Q39336818-7BD42DA8-0AF5-43EB-8D71-D80B9AB40D06 Q39575305-9EF8583F-FE52-4EFD-A629-8137D9AE272C Q40496908-3F2D50FE-AA66-4653-A630-A3279F28F887 Q40746356-7C11E6F4-0224-40AF-AC84-0817B7414496 Q45802306-B490873E-BCBF-4C56-9D85-60604E7D9757 Q52685080-91809754-9219-462B-BDFC-E66D65F2FC05 Q54961274-8EFDC1C3-5911-4C50-8842-EA3E09965523 Q55408705-63FAEC94-142F-4D70-BEEB-07FBEDB91F2C

P2860

Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children

http://www.wikidata.org/entity/Q35694752

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Noninferiority of miltefosine ...... eous leishmaniasis in children

@ast

Noninferiority of miltefosine ...... eous leishmaniasis in children

@en

type

label

Noninferiority of miltefosine ...... eous leishmaniasis in children

@ast

Noninferiority of miltefosine ...... eous leishmaniasis in children

@en

prefLabel

Noninferiority of miltefosine ...... eous leishmaniasis in children

@ast

Noninferiority of miltefosine ...... eous leishmaniasis in children

@en

P1433

Q35694752-DE27B5CB-9AC6-4ED0-8797-1D1B5E72487C

P1476

Q35694752-04E7D70B-6C14-452B-AFE1-5321FE86586D

P2093

Q35694752-05F0C15E-B0E8-4574-82F7-3349C886ED89

Q35694752-3BF49381-09EB-4BD6-A23B-77541EA10813

Q35694752-64AE619B-4E34-4713-8035-2F17541DCF1B

Q35694752-8D2D7979-2CCA-46F0-B505-D54D813B5117

Q35694752-AA93F46D-B809-461E-A21A-4003000BCACC

Q35694752-C1F5E112-3ECE-48F7-B26D-BD1910E59455

Q35694752-CA950925-C8A6-4123-9D81-D938F4D75BAF

Q35694752-E67D7AAB-F5E8-4CFD-BF83-035D932B27EE

Q35694752-EB6EE184-D97F-4617-8D05-93D375484850

Q35694752-ECFFF6B8-49C0-4B27-9D2F-DCCFFC5BE674

P2860

Q35694752-0166D5B2-B902-4211-8D3C-00F84767EACD

Q35694752-09A732B0-5D77-46F6-8505-85A6541C5009

Q35694752-0C6408B6-5BA9-4841-97CE-A22F626641DE

Q35694752-11631872-0D44-493F-A3C5-3494FEE74F49

Q35694752-11EC2C87-6665-43B3-82CE-B1C2D0A241C5

Q35694752-20BE5F1E-8499-4065-A2C1-0345369EF958

Q35694752-23075AAE-0A87-4289-B457-F010C5DA86C6

Q35694752-2EEB257D-7CD2-4CA1-A60D-4E3924304E11

Q35694752-34426C50-9829-403E-BB89-4329E3308790

Q35694752-36678E77-D100-4786-8B71-C3076FC0B3C2

P304

Q35694752-68C86ECF-EE09-4E85-97D2-AA27387A0A02

P31

Q35694752-8F83DE99-9665-46FD-9DB5-A746C5FAEA53

P356

Q35694752-6B6FD173-C8F8-4E2D-8C18-9ED42DED7E11

P407

Q35694752-1854425D-3AD8-4ED8-8FEE-B9A69729517F

P433

Q35694752-C818A04D-AD1F-4945-AA56-52096C38D3FC

P478

Q35694752-3595B70B-74E5-435A-BA32-E4133437D9C2

P50

Q35694752-5EC4137B-3CE9-48B5-9E92-99DEA8024020

Q35694752-9A9511BD-FE11-4FF3-9C10-EAE5339379E7

P577

Q35694752-58750AF2-A6E2-48A5-999D-0B353E976B01

P5875

Q35694752-508933C1-C66F-4675-B569-5263F4373999

P698

Q35694752-5475FBB7-D554-4C64-A730-EFB39002AD51

P932

Q35694752-CDF323FB-B7A0-47BE-BC70-A2C5AEB0A531

P356

P1433

The Journal of Infectious Diseases

P1476

Noninferiority of miltefosine ...... eous leishmaniasis in children

@en

P2093

Daniel Garcerant

http://www.w3.org/2001/XMLSchema#string

Luisa Consuelo Rubiano

http://www.w3.org/2001/XMLSchema#string

Luz Mery Montero

http://www.w3.org/2001/XMLSchema#string

Maria Ximena Rojas

http://www.w3.org/2001/XMLSchema#string

Martín Prager

http://www.w3.org/2001/XMLSchema#string

María Consuelo Miranda

http://www.w3.org/2001/XMLSchema#string

Mauricio Pérez

http://www.w3.org/2001/XMLSchema#string

Nancy Gore Saravia

http://www.w3.org/2001/XMLSchema#string

Ruben Santiago Nicholls

http://www.w3.org/2001/XMLSchema#string

Sandra Muvdi Arenas

http://www.w3.org/2001/XMLSchema#string

P2860

Distribution and etiology of leishmaniasis in Colombia.

Treatment of New World cutaneous leishmaniasis--a systematic review with a meta-analysis.

Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.

Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.

Oral miltefosine for Indian visceral leishmaniasis.

Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.

Miltefosine: issues to be addressed in the future.

Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.

Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management.

P304

684-692

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIR816

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

205

http://www.w3.org/2001/XMLSchema#string

P50

Isabel Rodríguez-Barraquer

P577

2012-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221933815

http://www.w3.org/2001/XMLSchema#string

P698

22238470

http://www.w3.org/2001/XMLSchema#string

P932

3266136

http://www.w3.org/2001/XMLSchema#string